



Curriculum Vitae

Youngil Koh, MD, PhD

**Seoul National University Hospital (SNUH)
101 Daehak-ro, Jongno-gu,
Seoul, 03080, Korea
go01@snu.ac.kr
+82-1091175012**

CAREER

2019.3 – Associate Professor, Hematology/Medical Oncology, SNUH, Seoul, Korea
2014.3 – 2019.2 Assistant Professor, Hematology/Medical Oncology, SNUH, Seoul, Korea
2013.5 - 2014.2 Clinical Fellow in Hematology/Medical Oncology, SNUH, Seoul, Korea
2010.3 - 2013.4 Public Service Doctor, Kkotdongnae, Gapyeong, Korea (Military service)
2010.2, Board Certified in Internal Medicine, SNUH, Seoul, Korea
2005.2, MD, Seoul National University College of Medicine, Seoul, Korea

EDUCATION

2018.2, PhD., Molecular and Clinical Oncology, Seoul National University, Seoul, Korea
2010.2, MS, Molecular and Clinical Oncology, Seoul National University, Seoul, Korea
2005.2, MD, Seoul National University College of Medicine, Seoul, Korea

Qualification ID

Medical doctor, ID 86015
Internal Medicine, ID 12468

AWARDS

1997 Silver medal, 38th International Mathematics Olympiad, Argentina
1998 Bronze medal, 39th International Mathematics Olympiad, Taiwan
2008 Best doctor for patients, Seoul National University Hospital
2008 Travel Award, American Society of Hematology Annual Meeting
2011 Best Oral Presentation Award, Korea Cancer Association Annual Meeting
2012 Best Oral Presentation Award, Korean Association for Clinical Oncology Annual Meeting

Clinical Trials

1. Phase II trial of Acalabrutinib with rituximab and lenalidomide in relapsed/refractory B-cell non-Hodgkin lymphoma
2. A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults
3. A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib(ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
4. A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib(ACP-196) in Subjects with Chronic Lymphocytic Leukemia
5. A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability,

Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)

6. A phase II trial to evaluate the efficacy of daratumumab with DCEP in Multiply Myeloma patients with Plasmacytoma who fail to achieve complete remission with bortezomib containing induction regimen
7. Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone versus carfilzomib with dexamethasone in patients with relapsed and/or refractory multiple myeloma previously treated with 1 to 3 prior lines
8. A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination with Standard of Care in Participants with Newly Diagnosed Multiple Myeloma
9. A Phase 2, Multicenter, Non-Randomized, Open-Label Study of RVT-1401 for the Treatment of Patients with Warm Autoimmune Hemolytic Anemia
10. A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
11. A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)
12. A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
13. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
14. A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
15. A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients ≥ 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy
16. An open-label, multicenter, phase 1 trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non Hodgkin's lymphoma
17. A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
18. An Adaptive Phase I/II study to assess safety, efficacy, pharmacokinetics and pharmacodynamics of RO7112689 in healthy volunteers and patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
19. A Phase Ib, open-label, dose-finding study of the JAK inhibitor INC424 tablets administered orally to patients with primary myelofibrosis (PMF), post-polycythemia veramyelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelet counts $\geq 50 \times 10^9/L$ and $< 100 \times 10^9/L$
20. Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant or intolerant (Response 2)
21. A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

22. Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
23. A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
24. A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
25. A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy
26. An Open-Label, Inpatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients with Paroxysmal Nocturnal Hemoglobinuria
27. A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation
28. A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma
29. An open-label, multicenter, phase 1 trial valuating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non-Hodgkin's lymphoma
30. A phase 3, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221(CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation.

PUBLICATION (1st or corresponding author only, including co-first author)

1. Koh Y, Lee HE, Im SA, et al. VEGF expression is related to good response and long progression-free survival in gastrointestinal stromal tumor patients treated with Sunitinib. Diagnostic molecular pathology : the American journal of surgical pathology, part B 2011;20:143-7.
2. Kim I, Koh Y, Yoon SS, et al. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. American journal of hematology 2013;88:10-5.
3. Park S, Koh Y, Jung SH, Chung YJ. Application of array comparative genomic hybridization in chronic myeloid leukemia. Methods in molecular biology 2013;973:55-68.
4. Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24:1026-31.
5. Koh Y, Kim I, Shin DY, et al. Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012;18:37-43.

6. Koh Y, Lee HE, Oh DY, et al. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use. *Japanese journal of clinical oncology* 2012;42:1020-7.
7. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2011;6:905-12.
8. Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. *Japanese journal of clinical oncology* 2011;41:548-54.
9. Koh Y, Kim DY, Park SH, et al. GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization. *Cancer genetics and cytogenetics* 2010;203:215-21.
10. Koh Y, Kim I, Bae JY, et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. *Japanese journal of clinical oncology* 2010;40:1037-45.
11. Koh Y, Lee HR, Song EY, et al. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA). *Leukemia research* 2010;34:1344-50.
12. Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. *Annals of hematology* 2010;89:725-31.
13. Koh Y, Jang B, Han SW, et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer* 2010;5:320-5.
14. Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. *Annals of hematology* 2010;89:201-6.
15. Koh Y, Kim TM, Jeon YK, et al. Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2009;20:1414-9.
16. Koh Y, Park J, Ahn KS, et al. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. *Annals of hematology* 2009;88:1089-97.
17. Koh Y, Park J, Bae EK, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. *International journal of hematology* 2009;90:1-5.

18. Koh Y, Jung WJ, Ahn KS, Yoon SS. Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient. *BioMed research international* 2014;2014:510408.
19. Koh Y, Lee SY, Kim I, et al. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. *Cancer chemotherapy and pharmacology* 2014;74:653-7.
20. Park H, Youk J, Kim I, et al. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. *Annals of hematology* 2016;95:1777-86.
21. Youk J, Koh Y, Kim JW, et al. A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. *Blood research* 2016;51:17-22.
23. Koh Y, Park I, Sun CH, et al. Detection of a Distinctive Genomic Signature in Rhabdoid Glioblastoma, A Rare Disease Entity Identified by Whole Exome Sequencing and Whole Transcriptome Sequencing. *Translational oncology* 2015;8:279-87.
24. Lee KW, Koh Y, Kim SB, et al. A Randomized, Multicenter, Phase II Study of Cetuximab With Docetaxel and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Cancer. *The oncologist* 2015;20:1119-20.
25. Byun JM, Koh Y, Shin DY, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. *Haematologica*. May 2017;102(5):e187-e190.
26. Park H, Youk J, Shin DY, et al. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. *BMC Cancer*. 2019;19(1):358.
27. Song H, Lim Y, Im H, et al. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Epstein-Barr virus). *Sci Rep*. 2019;9(1):3465.
28. Shin J, Ko YH, Oh SY, et al. Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. *Cancer Res Treat*. 2019.
29. Ock CY, Seo H, Kim DY, et al. Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia. *Leuk Lymphoma*. 2019;60(7):1775-1781.
30. Kim SA, Lee J, Moon JH, et al. Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors. *Ann Hematol*. 2019;98(2):501-510.
31. Koh Y, Lee JM, Woo GU, et al. FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. *Clin Nucl Med*. 2019;44(1):4-10.
32. Choi M, Jeon YK, Sun CH, et al. RTK-RAS pathway mutation is enriched in myeloid sarcoma. *Blood Cancer J*. 2018;8(5):43.
33. Min JW, Koh Y, Kim DY, et al. Identification of Novel Functional Variants of SIN3A and

- SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. *Mol Cells*. 2018;41(5):465-475.
35. Shin J, Kim D, Kim HL et al. Oncogenic effects of germline variants in lysosomal storage disease genes. *Genet Med* 2019.
 36. Suh KJ, Shin DY, Kim I et al. Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. *Ann Hematol* 2019; 98: 2357-2366.
 37. Kim D, Koh Y, Yoon SS. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. *Anticancer Res*. 2020;40(3):1395-1403.
 38. Yoon J, Lee S, Sun CH, et al. MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. *Thromb Res*. 2020;193:154-159.
 39. Ha JH, Lee C, Lee KS, et al. The molecular pathogenesis of Trichilemmal carcinoma. *BMC Cancer*. 2020;20(1):516.
 40. Byun JM, Song S, Koh Y, Yoon SS, Kim D. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. *Anticancer Res*. 2019;39(11):6273-6282.
 41. Lee S, Song S, Yoon SS, et al. Proper Read Filtering Method to Adequately Analyze Whole-Transcriptome Sequencing and RNA Based Immune Repertoire Sequencing Data for Tumor Milieu Research. *Cancers (Basel)* 2020;12.
 42. Ku J, Kim R, Kim D, et al. Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. *Commun Biol* 2020;3:630.